Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies block viral sites binding host’s cellular receptors. Virus infection is mediated by spike glycoprotein trimer virion surface via its receptor domain (RBD). Antibody response...
